AIM IHT
More than Money: James Fair
The picks and shovels business model has worked wonders for many British biotech companies. Abcam, for example, is one of AIM’s most successful companies. Bioventix has grown 5-fold in the last four years alone.
Fusion Antibodies is the biotech sector’s latest picks and shovels company. It develops and sells monoclonal antibodies for use in novel drugs and diagnostics equipment. Its proprietary platforms, which combine biotechnology with mathematical algorithms, are used to help pharma companies around the world develop new medicines.
We have spoken to the company’s chief financial officer James Fair.
Previous article Next article
